News

Artedrone successfully demonstrates the ability to autonomously perform end to end mechanical thrombectomy in various preclinical studies with the revolutionary SASHA autonomous micro-robotic solution

- Pre-Clinical Results Demonstrate the Potential of SASHA platform in democratizing mechanical thrombectomy procedures, marking a paradigm shift in stroke treatment

- New research findings build on Company momentum following recent appointment of Liane Teplitsky as CEO and addition of Nnamdi Njoku and Dan Raffi to Board of Directors

Artedrone reinforces
its governance with the appointment of
Liane Teplitsky as CEO,
Dan Raffi and Nnamdi Njoku to its Board of Directors.

Paris, Feb 04 2025 – Artedrone, a Truffle Capital’s medtech portfolio company developing an autonomous micro robotic platform to perform and democratize mechanical thrombectomy procedures to treat patients...